← Eichor
Study identifier: NCT06945887 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Treatment of Desmoid Fibromatosis With Arterial Embolization

Condition: Desmoid Fibromatosis  ·  Sponsor: Istituto Ortopedico Rizzoli

PhaseN/A
Planned participants20
Who can joinAll sexes, 12 Years to no upper limit
Healthy volunteersNo

About this study

Desmoid fibromatoses are rare and locally aggressive mesenchymal tumors. The current scientific evidence regarding the efficacy and safety of the treatment of desmoid fibromatosis by arterial embolization is constituted by several retrospective and prospective studies. These studies report promising results through the use of chemoembolization, that is, arterial embolization using particles loaded with chemotherapy. Instead, the type of treatment we propose would consist of injection of embolizing material without the use of chemotherapy, based on the positive results we have consistently reported over the years on arterial embolization of musculoskeletal tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Giancarlo Facchini, Medicine and Surgery  ·  +39 0516366836  ·  giancarlo.facchini@ior.it

Always discuss trial participation with your own doctor first.

Locations (1)

Istituto Ortopedico RizzoliBologna, BO, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06945887